Search results
Results from the WOW.Com Content Network
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4][5] The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology ...
Citing the U.S. agency's decision, GSK cut its forecast for 2024 vaccine sales. It now expects that business to grow by a low to mid-single digit percentage, from an earlier expectation of high ...
(Reuters) -GSK CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, thanks to a big jump in performance-related pay, the British drugmaker's annual report ...
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [8][9]
October 4, 2024 at 2:31 PM. GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report. The U.S. government has granted $72 million to European pharma giants GSK ...
Unilever offered £50 billion for the business in 2022, in a bid which GSK rejected. [11] Nestlé examined the possibility of a bid in conjunction with Reckitt. [12] In October 2023, GSK reduced its ownership share in Haleon to just over 7.4%, [13] and again in January 2024 down to 4.2%. [14]